DENTSPLY SIRONA Inc.

DENTSPLY SIRONA Inc. (the “Company”) is unable to timely file, without unreasonable effort and expense, its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 (the “Form 10-Q”). As previously reported, the Company was unable to timely file its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022 and June 30, 2022 as a result of an internal investigation commenced in March 2022 by the Audit and Finance Committee of the Company’s Board of Directors, as described in the Explanatory Notes to Amendment No. 1 to our Annual Report on Form 10-K/A for the fiscal year ended December 31, 2021 filed on November 7, 2022 (the “Form 10-K/A”) and Amendment No. 1 to the Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 filed on November 7, 2022 (the “Form 10-Q/A”). The internal investigation has been completed. The Company also filed its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022 and June 30, 2022 on November 7, 2022. Given the demands on management’s time that were required to complete and file the 2021 Form 10-K/A, the Form 10-Q/A, and the delinquent Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022 and June 30, 2022, the Company requires additional time to complete its goodwill and intangible assets impairment analyses and final review of its unaudited interim consolidated financial statements and other disclosures in the Form 10-Q. The Company fully expects to file the Form 10-Q within the extension period of five calendar days as provided under Rule 12b-25 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company does not expect any changes to previously reported select preliminary financial results, including the range of anticipated pre-tax charges for goodwill and intangible asset impairment previously provided in its press release furnished as Exhibit 99.1 to the Company’s Current Report on Form 8-K filed on Nov

DENTSPLY SIRONA Inc. (the “Company”) is unable to file its Quarterly Report on Form 10-Q for the period ended June 30, 2022 (the “Second Quarter Form 10-Q”) by the prescribed date of August 9, 2022, without unreasonable effort or expense, for the reasons described below. As previously disclosed, the Audit and Finance Committee of the Company’s Board of Directors (the “Audit Committee”) is conducting an internal investigation regarding certain financial reporting matters. The investigation is ongoing. The Audit Committee continues to work diligently with independent counsel and advisors to complete its investigation as soon as possible. However, the Company cannot predict the duration or outcome of the investigation. In the course of the investigation, the Company has also evaluated certain other accounting practices. As a result of this review, the Company anticipates certain adjustments will be made to the previously announced preliminary first quarter financial results, and the Company is currently evaluating whether fiscal year 2021 reported financial results also require adjustments. As previously disclosed, the Company has voluntarily contacted the SEC to advise it that an internal investigation is underway, and the Audit Committee intends to provide additional information to the SEC as its investigation proceeds. The Company intends to fully cooperate with the SEC regarding this matter. The Company will work to finalize its financial statements and review of internal controls and procedures, including the evaluation of any deficiencies in internal controls over financial reporting, as soon as practicable, but does not expect to be in a position to file the Second Quarter 10-Q within five calendar days following the prescribed due date

DENTSPLY SIRONA Inc. (the “Company” or “Dentsply Sirona”) is unable to file its Quarterly Report on Form 10- Q for the period ended March 31, 2022 (the “Form 10-Q”) by the prescribed date of May 10, 2022, without unreasonable effort or expense, for the reasons described below. In March 2022, the Audit and Finance Committee of the Company’s Board of Directors (the “Audit Committee”) commenced an internal investigation of allegations regarding certain financial reporting matters submitted by current and former employees of the Company. The Audit Committee’s investigation is focused on the Company’s use of incentives to sell products to distributors in the third and fourth quarters of 2021 and whether those incentives were appropriately accounted for and the impact of those sales was adequately disclosed in the Company’s periodic reports filed with the Securities and Exchange Commission (“SEC”). The Audit Committee is also investigating allegations that certain former and current members of senior management directed the Company’s use of these incentives and other actions to achieve executive compensation targets in 2021. The Audit Committee has retained independent outside counsel, which has engaged a forensic accounting firm, to assist in its investigation. The Company has voluntarily contacted the SEC to advise it that an internal investigation is underway, and the Audit Committee intends to provide additional information to the SEC as the investigation proceeds. The investigation is ongoing and the Company cannot predict the duration or outcome of the investigation. As a result, the Company has not yet finalized its financial statements or its assessment of the impact of the investigation on its historical financial statements or for the financial statements for the three months ended March 31, 2022, and is therefore unable to file the Form 10-Q on a timely basis